SEW2871 Protects from Experimental Colitis Through Reduced Epithelial Cell Apoptosis and Improved Barrier Function in Interleukin-10 Gene-Deficient Mice

Jianning Dong,Honggang Wang,Jie Zhao,Jing Sun,Tenghui Zhang,Lugen Zuo,Weiming Zhu,Jianfeng Gong,Yi Li,Lili Gu,Jieshou Li

DOI: https://doi.org/10.1007/s12026-015-8625-5

2015-01-01

Immunologic Research

Abstract:Loss of intestinal epithelial barrier function including typical tight junction changes and epithelial cell apoptosis plays an important role in Crohn’s disease. SEW2871, a selective sphingosine-1-phosphate type-1 receptor agonist, has been proven to be efficient in protecting against colitis in IL-10−/− mice in our previous study. Here we performed additional studies to investigate whether treatment with SEW2871 was associated with an improved epithelial barrier function in IL-10−/− mice. SEW2871 was administered by gavage at a dose of 20 mg/kg/day for 2 weeks to IL-10−/− mice. Severity of colitis, CD4+ T cells in colon lamina propria and proinflammatory cytokine productions were evaluated. Furthermore, intestinal permeability, tight junction (occludin and ZO-1) expressions and distributions, as well as epithelial cell apoptosis, were also assessed. SEW2871 treatment attenuated established colitis associated with decreased CD4+ T cells in colon lamina propria and reduced TNF-α and IFN-γ levels. Moreover, enhanced barrier function, which resulted from ameliorated tight junction (occludin and ZO-1) expressions and suppressed epithelial cell apoptosis, was found to contribute to the therapeutic effects. SEW2871 treatment protects from colitis in IL-10−/− mice through reduced epithelial cell apoptosis and improved barrier function. Thus, targeting sphingosine-1-phosphate may represent a new therapeutic approach in Crohn’s disease.